Abstract
Aim Childhood chronic myeloid leukemia (CML) is rare myeloproliferative disorder, and diagnosed mostly in adult, representing for 10% of all CML, and accounts for up to 2-3% of all childhood leukemia. Tyrosine kinase inhibitor (TKI), mostly Imatinib mesylate, is now used in the frontline standard treatment of CML in chronic phase. The aim of this study is to investigate the growth effect of TKI treatment in childhood CML.
Highlights
Aim Childhood chronic myeloid leukemia (CML) is rare myeloproliferative disorder, and diagnosed mostly in adult, representing for 10% of all CML, and accounts for up to 2-3% of all childhood leukemia
The aim of this study is to investigate the growth effect of Tyrosine kinase inhibitor (TKI) treatment in childhood CML
Submit your manuscript to BioMed Central and take full advantage of:
Summary
Yeon Jin Jeon*, In Ah Jung, Won-Kyoung Cho, Jae-Wook Lee, Nak-Gyun Chung, Min-Ho Jung, Bin Cho, Byung-Kyu Suh. From 8th APPES Biennial Scientific Meeting Darwin, Australia. Aim Childhood chronic myeloid leukemia (CML) is rare myeloproliferative disorder, and diagnosed mostly in adult, representing for 10% of all CML, and accounts for up to 2-3% of all childhood leukemia. Tyrosine kinase inhibitor (TKI), mostly Imatinib mesylate, is used in the frontline standard treatment of CML in chronic phase.
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
